A5034560778- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
- Cancer Genomics and Diagnostics
- HIV/AIDS drug development and treatment
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Cancer therapeutics and mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- Bone health and treatments
- Cancer Mechanisms and Therapy
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Endoplasmic Reticulum Stress and Disease
- Chemokine receptors and signaling
- Genomic variations and chromosomal abnormalities
- Computational Drug Discovery Methods
- Acute Myeloid Leukemia Research
- Chromosomal and Genetic Variations
NYU Langone Health
2019-2025
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2019-2024
New York University
2019-2024
Institute of Cancer Research
2011-2023
University of Birmingham
2000-2023
University of Arkansas for Medical Sciences
2014-2023
University of Leeds
2001-2023
Leeds Teaching Hospitals NHS Trust
2004-2023
Institute of Cancer Research
2015-2023
University Hospitals Birmingham NHS Foundation Trust
2023
High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited.
Abstract Much has been learned regarding the biology and clinical implications of genetic abnormalities in multiple myeloma. Because recent advances field, an International Workshop was held Paris February 2003. This summary describes consensus recommendations arising from that meeting with special emphasis on novel observations. For instance, it is increasingly clear translocations involving immunoglobulin heavy-chain locus are important for pathogenesis one-half patients. As a corollary,...
At the molecular level, myeloma is characterized by copy number abnormalities and recurrent translocations into immunoglobulin heavy chain locus. Novel methods, such as massively parallel sequencing, have begun to describe pattern of tumor-acquired mutations, but their clinical relevance has yet be established.We performed whole-exome sequencing for 463 patients who presented with were enrolled onto National Cancer Research Institute Myeloma XI trial, whom complete cytogenetic outcome data...
Early mortality in multiple myeloma (MM) is usually attributed to combined effects of active disease and comorbid factors. We have studied early deaths a series large multicenter trials assess direct causes death, their predictability, whether current management strategies reduced frequency.A total 3,107 newly diagnosed patients entered onto United Kingdom Medical Research Council MM from 1980 2002 were studied. Trial files, final clinical summaries, postmortem reports analyzed.Death within...
To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated MRC (Medical Research Council) Myeloma IX trial.Multiparameter flow cytometry (MFC) was used to assess MRD after induction therapy (n = 378) and at day 100 autologous stem-cell transplantation (ASCT; n 397) intensive-pathway end non-intensive-pathway 245).In patients, absence ASCT highly predictive a favorable outcome (PFS, P < .001; OS, .0183). This advantage...
Patients with newly diagnosed multiple myeloma (NDMM) high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used identify patients, each which has significant weaknesses. Inclusion molecular into risk stratification could resolve current challenges. In a genome-wide analysis largest set and clinical data established date from NDMM, as part Myeloma Genome Project, we defined DNA drivers...
The aim of International Myeloma Working Group was to develop practical recommendations for the use magnetic resonance imaging (MRI) in multiple myeloma (MM).An interdisciplinary panel clinical experts on MM and bone disease developed value MRI based data published through March 2014.MRI has high sensitivity early detection marrow infiltration by cells compared with other radiographic methods. Thus, detects involvement patients much earlier than myeloma-related destruction, no radiation...
Abstract In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an imbalanced distribution frequently observed in medical imaging. Here, we perform multi-region sequencing, including iliac crest and radiology-guided focal lesion specimens from 51 patients to gain insight into spatial clonal architecture. We demonstrate genomic heterogeneity more than 75% patients,...
Abstract Recent evidence suggests a role for natural killer (NK) cells in the control of multiple myeloma. We show that expression NK cell receptor DNAM-1 (CD226) is reduced on CD56dim from myeloma patients with active disease compared remission and healthy controls. This suggested this might play NK-myeloma interactions. The ligands Nectin-2 (CD112) poliovirus (PVR; CD155) were expressed by most patient samples analyzed. killing patient-derived myelomas expressing PVR and/or was dependent,...
Patients with multiple myeloma treated lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of on overall survival in this setting has been inconsistent between individual studies. Minimal data are available the more aggressive disease states, such as patients cytogenetic high-risk or ineligible for We aimed to assess versus observation newly diagnosed myeloma, including risk and...